Inclusion Criteria:  Age 18-60 for the main trial cohort Age ≥ 61 years and eligible for AVD as determined by CIRS-G score and investigator for the exploratory cohort First diagnosis of treatment-naïve cHL  Early-stage unfavorable disease (i.e. stage IA, IB and IIA with risk factors a-d, stage IIB with risk factors c-d):  large mediastinal mass extranodal lesion(s) elevated erythrocyte sedimentation rate  ≥ 3 nodal areas  Exclusion Criteria:  Presence of nodular-lymphocyte predominant Hodgkin lymphoma, grey-zone lymphoma and/or central nervous system involvement of lymphoma